Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.

Alejandro Piscoya RiveraAngela Parra Del RiegoRenato Cerna-ViacavaJonathon RoccoYuani M RomanAngel A EscobedoVinay PasupuletiC Michael WhiteAdrian V Hernández

Published in: PloS one (2022)

In comparison to SOC or placebo, TCZ reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in RCTs in hospitalized COVID-19 patients. Other clinical outcomes were not significantly impacted. TCZ did not have effect on AEs, except a significant increased neutropenia risk in RCTs. TCZ has a potential role in the treatment of hospitalized COVID-19 patients.

Keyphrases

mechanical ventilation
sars cov
intensive care unit
acute respiratory distress syndrome
rheumatoid arthritis
randomized controlled trial
clinical trial
combination therapy
replacement therapy